Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.
A 65 year old woman with long-standing Addison's disease treated with oral glucocorticoid and mineralocorticoid replacement had persistently high ACTH levels, inadequate suppression of ACTH on low-dose dexamethasone, sellar enlargement, and pigmentation, and thus resembled patients alleged to develop corticotropinomas while on oral replacement for adrenal insufficiency. Since animal studies suggested that rapid rises of corticosteroids within the physiologic range can inhibit ACTH release, we administered brief infusions of cortisol every three hours with total daily dose equal to her chronic dose. Prompt suppression of ACTH and immunoreactive beta-endorphin occurred during each cortisol dose profiled, suggesting a role for ultradian cortisol fluctuations in tonic inhibition of ACTH secretion in humans, and a possible therapeutic benefit of mimicking ultradian cortisol rhythms during replacement therapy.
D000224:Addison Disease / Q000150:complications / Q000188:drug therapy*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000368:Aged; D004723:Endorphins / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D010903:Pituitary Gland, Anterior / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism*; D011673:Pulsatile Flow; D001615:beta-Endorphin
D004723:Endorphins; D005938:Glucocorticoids; D001615:beta-Endorphin; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone